call 1800 257 600 email [email protected]

Clinical Trials

Cancer Type

State

Phase

Treatment

Inhibitor

A Centralized Platform study for Functional High Risk Multiple Myeloma: Domain 1

ACTRN 12625000438459 Brief Summary The purpose of this platform study is to…

Read more arrow_forward

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

NCT 05763004 Brief Summary The goal of this clinical trial is to…

Read more arrow_forward

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

NCT 04735575 Brief Summary The primary purpose of this study is to…

Read more arrow_forward

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT 04973605 Brief Summary Study consists of two parts, a part 1…

Read more arrow_forward

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

NCT 06425991 Brief Summary The purpose of this study is to…

Read more arrow_forward

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

NCT 06208150 Brief Summary The purpose of this study is to…

Read more arrow_forward

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (PLYCOM)

NCT 05583617 Brief Summary CO43923 is a platform study that will evaluate…

Read more arrow_forward

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT 05927571 Brief Summary The purpose of the study is to evaluate…

Read more arrow_forward

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (MonumenTAL-8)

NCT 06550895 Brief Summary The purpose of this study is to…

Read more arrow_forward

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (aMMbition)

NCT 06577025 Brief Summary The purpose of this study is to…

Read more arrow_forward

Knowledge Base

Cancer Types Cancer Services Health Professionals

How we help you

Our support knows no limits, which means we do whatever it takes to be there for all you need.

How we help you View the Rare Cancer Support Guide

Can’t find what you’re looking for?

We have a friendly team available to chat about any questions you may have, or just to lend an ear if you’re having a tough time.

Call 1800 257 600 Have us call you